Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.

ABSTRACT:

Background

Current availability of several biologic treatments for severe asthma makes it possible to choose the most appropriate for each patient. Sometimes a good percentage of patients with severe asthma may be eligible for biologics that target either the allergic phenotype or the eosinophilic one, but not all respond to that selected as first choice. The aim of our real-life study was to assess whether, for patients with severe eosinophilic allergic asthma, not previously controlled by the anti-IgE omalizumab, the shift to another biologic targeting interleukin-5, such as mepolizumab, may represent a good therapeutic choice.

Methods

A total of 41 consecutive patients with severe, persistent allergic, eosinophilic asthma, uncontrolled despite treatment with omalizumab, w

SUBMITTER: Carpagnano GE 

PROVIDER: S-EPMC7268123 | biostudies-literature | 2020 Jan-Dec

REPOSITORIES: biostudies-literature